BioMarin Pharmaceutical Inc. (BMRN)

83.19
0.72 0.87
NASDAQ : Health Technology
Prev Close 82.47
Open 82.16
Day Low/High 82.16 / 83.55
52 Wk Low/High 79.13 / 106.74
Volume 888.02K
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 179.07M
Market Cap 14.75B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

PTC Therapeutics Getting Cold Shoulder From Regulators on Duchenne Drug Appeal

On Monday, PTC said the U.S. Food and Drug Administration denied an appeal of the Translarna refuse-to-file letter issued last February.

Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics

Pardon Me, but I Have a Few Things to Say... Seattle Genetics, Biomarin, Sarepta, TG Therapeutics

Are the Baker Brothers selling Seattle Genetics? Biomarin CEO throws shade on Sarepta. TG Therapeutics management adds to its credibility problem.

New Setback for Sanofi's Lantus Increases Need for M&A

New Setback for Sanofi's Lantus Increases Need for M&A

UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.

Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition

Biotech Stock Mailbag: Sarepta Therapeutics Approval Edition

TheStreet's Adam Feuerstein answers reader questions about Sarepta Therapeutics and its newly approved drug Exondys 51 for Duchenne muscular dystrophy.

These 5 Biotech Stocks Are Ready for a Volatility Break

These 5 Biotech Stocks Are Ready for a Volatility Break

The squeeze is on these stocks, and they are poised for volatile moves.

BioMarin Announces Two Oral And 16 Poster Presentations At Society For The Study Of Inborn Errors Of Metabolism 2016 Annual Meeting

BioMarin Announces Two Oral And 16 Poster Presentations At Society For The Study Of Inborn Errors Of Metabolism 2016 Annual Meeting

Oral Presentations Include Updated Long-Term Data from Extension Study of Brineura™ (Cerliponase Alfa) in Children with CLN2 Disease, and Long-Term Safety and Efficacy Data of Pegvaliase in Adults with PKU

Forbes Ranks BioMarin 10th Most Innovative Company In The World

Forbes Ranks BioMarin 10th Most Innovative Company In The World

For the third consecutive year, BioMarin ranks in top 10 on list

BioMarin (BMRN) Stock Surges on Takeover Speculation

BioMarin (BMRN) Stock Surges on Takeover Speculation

BioMarin (BMRN) stock was trading sharply higher this morning after Pfizer (PFE) beat out Sanofi (SNY) to purchase Medivation (MDVN).

Facebook Stands Out and FormFactor Has a Good Start

Facebook Stands Out and FormFactor Has a Good Start

Overall, this is still a good environment for stock picking.

Cramer: Companies Are Issuing a Lot of Paper

Cramer: Companies Are Issuing a Lot of Paper

They're striking while the iron is hottest to raise money, reduce debt.

BioMarin (BMRN) Stock Tumbles in After-Hours Trading on Public Offering

BioMarin (BMRN) Stock Tumbles in After-Hours Trading on Public Offering

BioMarin (BMRN) stock is trading lower after the market close after announcing a public offering of common stock.

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas: Biomarin Pharmaceutical (BMRN) Is Today's Post-Market Leader Stock

Trade-Ideas LLC identified Biomarin Pharmaceutical (BMRN) as a post-market leader candidate

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Biomarin Hemophilia Gene Therapy Advances on Strong Study Results

Biomarin Hemophilia Gene Therapy Advances on Strong Study Results

BMN 270 is one of the most important drugs in Biomarin's research pipeline and key driver of future revenue and earnings.

Roche Beats First-Half Forecasts as Cancer Drug Sales Rise

Roche Beats First-Half Forecasts as Cancer Drug Sales Rise

The Swiss pharmaceuticals company confirms a forecast for full-year sales to increase in the low to mid-single digits, and for earnings per share to grow faster than revenue.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

TheStreet Quant Rating: D+ (Sell)